Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2013 Sep 6;2013(9):CD004439.
doi: 10.1002/14651858.CD004439.pub3.

Antibiotics for treating chronic osteomyelitis in adults

Lucieni O Conterno  1 , Marilia D Turchi
Affiliations
Meta-Analysis

Antibiotics for treating chronic osteomyelitis in adults

Lucieni O Conterno et al. Cochrane Database Syst Rev. .

Abstract

Background: Chronic osteomyelitis is generally treated with antibiotics and surgical debridement but can persist intermittently for years with frequent therapeutic failure or relapse. Despite advances in both antibiotic and surgical treatment, the long-term recurrence rate remains around 20%. This is an update of a Cochrane review first published in 2009.

Objectives: To determine the effects of different systemic antibiotic treatment regimens for treating chronic osteomyelitis in adults.

Search methods: We searched the Cochrane Bone, Joint and Muscle Trauma Group Specialised Register (October 2012), the Cochrane Central Register of Controlled Trials (The Cochrane Library 2012, Issue 9), MEDLINE (January 1948 to September Week 4 2012), EMBASE (January 1980 to 2012 Week 40), LILACS (October 2012), the WHO International Clinical Trials Registry Platform (June 2012) and reference lists of relevant articles.

Selection criteria: Randomised controlled trials (RCTs) or quasi-RCTs addressing the effects of different antibiotic treatments given after surgical debridement for chronic osteomyelitis in adults.

Data collection and analysis: Two review authors independently screened papers for inclusion, extracted data and appraised risk of bias in the included trials. Where appropriate, we pooled data using the fixed-effect model.

Main results: We included eight small trials involving a total of 282 participants with chronic osteomyelitis. Data were available from 248 participants. Most participants were male with post-traumatic osteomyelitis, usually affecting the tibia and femur, where recorded. The antibiotic regimens, duration of treatment and follow-up varied between trials. All trials mentioned surgical debridement before starting on antibiotic therapy as part of treatment, but it was unclear in four trials whether all participants underwent surgical debridement.We found that study quality and reporting were often inadequate. In particular, we judged almost all trials to be at moderate to high risk of bias due to failure to conceal allocation and inadequate follow-up.Four trials compared oral versus parenteral route for administration of antibiotics. There was no statistically significant difference between the two groups in the remission at the end of treatment (70/80 versus 58/70; risk ratio (RR) 1.04, 95% confidence interval (CI) 0.92 to 1.18; four trials, 150 participants). There was no statistically significant difference between the two groups in the remission rate 12 or more months after treatment (49/64 versus 44/54; RR 0.94, 95% CI 0.78 to 1.13; three trials, 118 participants). There was also no significant difference between the two groups in the occurrence of mild adverse events (11/64 versus 8/54; RR 1.08, 95% CI 0.49 to 2.42; three trials, 118 participants) or moderate and severe adverse events (3/49 versus 4/42; RR 0.69, 95% CI 0.19 to 2.57; three trials, 91 participants). Superinfection occurred in participants of both groups (5/66 in the oral group versus 4/58 in the parenteral group; RR 1.08, 95% CI 0.33 to 3.60; three trials, 124 participants).Single trials with few participants found no statistical significant differences for remission or adverse events for the following four comparisons: oral only versus parenteral plus oral administration; parenteral plus oral versus parenteral only administration; two different parenteral antibiotic regimens; and two different oral antibiotic regimens. No trials compared different durations of antibiotic treatment for chronic osteomyelitis, or adjusted the remission rate for bacteria species or severity of disease.

Authors' conclusions: Limited and low quality evidence suggests that the route of antibiotic administration (oral versus parenteral) does not affect the rate of disease remission if the bacteria are susceptible to the antibiotic used. However, this and the lack of statistically significant differences in adverse effects need confirmation. No or insufficient evidence exists for other aspects of antibiotic therapy for chronic osteomyelitis.The majority of the included trials were conducted over 20 years ago and currently we are faced with a far higher prevalence of bacteria that are resistant to many of the available antibiotics used for healthcare. This continuously evolving bacterial resistance represents another challenge in the choice of antibiotics for treating chronic osteomyelitis.

PubMed Disclaimer

Conflict of interest statement

Lucieni O Conterno ‐ none known Marilia D Turchi ‐ none known

Figures

1
1
Study flow diagram.
2
2
Risk of bias summary: review authors' judgements about each risk of bias item for each included study
3
3
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies
1.1
1.1. Analysis
Comparison 1 Oral antibiotic versus parenteral antibiotic (AB), Outcome 1 Remission at the end of treatment.
1.2
1.2. Analysis
Comparison 1 Oral antibiotic versus parenteral antibiotic (AB), Outcome 2 Remission at least 12 months after the end of treatment.
1.3
1.3. Analysis
Comparison 1 Oral antibiotic versus parenteral antibiotic (AB), Outcome 3 Mild adverse events.
1.4
1.4. Analysis
Comparison 1 Oral antibiotic versus parenteral antibiotic (AB), Outcome 4 Moderate or severe adverse events.
1.5
1.5. Analysis
Comparison 1 Oral antibiotic versus parenteral antibiotic (AB), Outcome 5 Superinfection.
2.1
2.1. Analysis
Comparison 2 Oral antibiotic versus parenteral plus oral antibiotic, Outcome 1 Remission at least 12 months after the end of the treatment.
2.2
2.2. Analysis
Comparison 2 Oral antibiotic versus parenteral plus oral antibiotic, Outcome 2 Adverse events.
3.1
3.1. Analysis
Comparison 3 Parenteral plus oral antibiotics versus parenteral antibiotic, Outcome 1 Remission at least 12 months after the end of treatment.
3.2
3.2. Analysis
Comparison 3 Parenteral plus oral antibiotics versus parenteral antibiotic, Outcome 2 Adverse events.
4.1
4.1. Analysis
Comparison 4 Parenteral antibiotic 1 (ceftazidime) versus parenteral antibiotic 2 (ticarcillin plus tobramycin), Outcome 1 Remission at least 12 months after the end of the treatment.
4.2
4.2. Analysis
Comparison 4 Parenteral antibiotic 1 (ceftazidime) versus parenteral antibiotic 2 (ticarcillin plus tobramycin), Outcome 2 Adverse events.
4.3
4.3. Analysis
Comparison 4 Parenteral antibiotic 1 (ceftazidime) versus parenteral antibiotic 2 (ticarcillin plus tobramycin), Outcome 3 Superinfection.
5.1
5.1. Analysis
Comparison 5 Oral antibiotic 1 (ciprofloxacin) versus oral antibiotic 2 (lomefloxacin), Outcome 1 Remission at least 12 months after the end of treatment.
5.2
5.2. Analysis
Comparison 5 Oral antibiotic 1 (ciprofloxacin) versus oral antibiotic 2 (lomefloxacin), Outcome 2 Adverse events.
See this image and copyright information in PMC

Update of

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Euba 2009 {published data only}
    1. Cardenal JA. Oral rifampin‐cotrimoxazole combination versus intravenous cloxacillin in chronic staphylococcal osteomyelitis: a long‐term follow‐up trial. http://isrctn.org/ISRCTN27058472 (accessed 20 April 2013) 2008. - PMC - PubMed
    1. Euba G, Murillo O, Fernandez‐Sabé N, Mascaró J, Cabo J, Perez A, et al. Long‐term follow‐up trial of oral rifampin‐cotrimoxazole combination versus intravenous cloxacillin in treatment of chronic staphylococcal osteomyelitis. Antimicrobial Agents and Chemotherapy 2009;53(6):2672‐6. - PMC - PubMed
Gentry 1990 {published data only}
    1. Gentry LO, Rodriguez GG. Oral ciprofloxacin compared with parenteral antibiotics in the treatment of osteomyelitis. Antimicrobial Agents and Chemotherapy 1990;34(1):40‐3. - PMC - PubMed
Gentry 1991 {published data only}
    1. Gentry LO, Rodriguez‐Gomez G. Ofloxacin versus parenteral therapy for chronic osteomyelitis. Antimicrobial Agents and Chemotherapy 1991;35(3):538‐41. - PMC - PubMed
Gomis 1999 {published data only}
    1. Gomis M, Barberan J, Sanchez B, Khorrami S, Borja J, Garcia BJ. Oral ofloxacin versus parenteral imipenem‐cilastatin in the treatment of osteomyelitis [Ofloxacino oral versus imipenem‐cilastatina intravenoso en el tratamiento de la osteomielitis]. Revista Espanola de Quimioterapia 1999;12(3):244‐9. - PubMed
Greenberg 2000 {published data only}
    1. Greenberg RN, Newman MT, Shariaty S, Pectol RW. Ciprofloxacin, lomefloxacin, or levofloxacin as treatment for chronic osteomyelitis. Antimicrobial Agents and Chemotherapy 2000;44(1):164‐6. - PMC - PubMed
Mader 1990 {published data only}
    1. Mader JT, Cantrell JS, Calhoun J. Oral ciprofloxacin compared with standard parenteral antibiotic therapy for chronic osteomyelitis in adults. Journal of Bone Joint Surgery ‐ American Volume 1990;72(1):104‐10. - PubMed
Norden 1986 {published data only}
    1. Norden CW, Bryant R, Palmer D, Montgomerie JZ, Wheat J. Chronic osteomyelitis caused by Staphylococcus aureus: controlled clinical trial of nafcillin therapy and nafcillin‐rifampin therapy. Southern Medical Journal 1986;79(8):947‐51. - PubMed
    1. Norden CW, Fierer J, Bryant RE. Chronic Staphylococcus osteomyelitis: treatment with regimens containing rifampin. Reviews of Infectious Diseases 1983;5(Suppl 3):S495‐501. - PubMed
Sheftel 1986 {published data only}
    1. Sheftel TG, Mader JT. Randomized evaluation of ceftazidime or ticarcillin and tobramycin for the treatment of osteomyelitis caused by gram‐negative bacilli. Antimicrobial Agents and Chemotherapy 1986;29(1):112‐5. - PMC - PubMed

References to studies excluded from this review

Baumgartner 1983 {published data only}
    1. Baumgartner JD, Glauser MP. Comparative study of imipenem in severe infections. Journal of Antimicrobial Chemotherapy 1983;12(Suppl D):141‐8. - PubMed
Giamarellou 1989 {published data only}
    1. Giamarellou H, Perdikaris G, Galanakis N, Davoulos G, Mandragos K, Sfikakis P. Pefloxacin versus ceftazidime in the treatment of a variety of gram‐negative‐bacterial infections. Antimicrobial Agents and Chemotherapy 1989;33(8):1362‐7. - PMC - PubMed
Greenberg 1987 {published data only}
    1. Greenberg RN, Tice AD, Marsh PK, Craven PC, Reilly PM, Bollinger M, et al. Randomized trial of ciprofloxacin compared with other antimicrobial therapy in the treatment of osteomyelitis. American Journal of Medicine 1987;82(4A):266‐9. - PubMed
Hedstrom 1975 {published data only}
    1. Hedstrom SA. Treatment of chronic staphylococcal osteomyelitis with cloxacillin and dicloxacillin ‐ a comparative study in 12 patients. Scandinavian Journal of Infectious Diseases 1975;7(1):55‐7. - PubMed
Ingianni 2007 {published data only}
    1. Ingianni A, Lampis G, Laconi S, Cariello D, Pompei R. Standard versus specific therapy for chronic osteomyelitis treatment. American Journal of Infectious Diseases 2007;3(3):128‐33.
Loffler 1986 {published data only}
    1. Loffler L, Bauernfeind A, Keyl W. Sulbactam/ampicillin versus cefotaxime as initial therapy in serious soft tissue, joint and bone infections. Drugs 1988;35(Suppl 7):46‐52. - PubMed
    1. Loffler L, Bauernfeind A, Keyl W, Hoffstedt B, Piergies A, Lenz W. An open, comparative study of sulbactam plus ampicillin vs. cefotaxime as initial therapy for serious soft tissue and bone and joint infections. Reviews of Infectious Diseases 1986;8(Suppl 5):S593‐8. - PubMed
Mandell 1989 {published data only}
    1. Mandell LA, Bergeron MG, Ronald AR, Vega C, Harding G, Saginur R, et al. Once‐day therapy with ceftriaxone compared with daily multiple‐dose therapy with cefotaxime for serious bacterial infections: a randomised, double‐blind study. Journal of Infectious Diseases 1989;160(3):433‐41. - PubMed
Marier 1983 {published data only}
    1. Marier RL, McCloskey RV, Dickenson G, Sanders CV, Aldridge KE, Hoffman T, et al. Comparative clinical trial of imipenem‐cilastatin (N‐formimidoyl‐thienamycin‐dehydropeptidase inhibitor) and cefazolin. Journal of Antimicrobial Chemotherapy 1983;12(Suppl D):133‐9. - PubMed
Marriott 2008 {published data only}
    1. Marriott R, Rubayi S. Successful truncated osteomyelitis treatment for chronic osteomyelitis secondary to pressure ulcers in spinal cord injury patients. Annals of Plastic Surgery 2008;61(4):425‐9. - PubMed
Nguyen 2009 {published data only}
    1. Nguyen S, Pasquet A, Legout L, Beltrand E, Dubreuil L, Migaud H, et al. Efficacy and tolerance of rifampicin–linezolid compared with rifampicin–cotrimoxazole combinations in prolonged oral therapy for bone and joint infections. Clinical Microbiology and Infection 2009;15(12):1163‐9. - PubMed
Paladino 1991 {published data only}
    1. Paladino JA, Sperry HE, Backes JM, Gelber JA, Serrianne, DJ, Cumbo TJ, et al. Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics. American Journal of Medicine 1991;91(5):462‐70. - PubMed
Peacock 1989 {published data only}
    1. Peacock JE Jr, Pegram PS, Weber SF, Leone PA. Prospective, randomised comparison of sequential intravenous followed by oral ciprofloxacin with intravenous ceftazidime in the treatment of serious infections. American Journal of Medicine 1989;87(5A):185S‐90S. - PubMed
Reinhardt 1986 {published data only}
    1. Reinhardt JF, Jonnston L, Ruane P, Johnson CC, Ingram‐drake L, MacDonald K, et al. A randomised, double‐blind comparison of sulbactam/ampicillin and clindamycin for the treatment of aerobic and aerobic‐anaerobic infections. Reviews of Infectious Diseases 1986;8(Suppl 5):S569‐75. - PubMed
Siebert 1985 {published data only}
    1. Siebert WT, Kopp PE. Ticarcillin plus clavulanic acid versus moxalactam therapy of osteomyelitis, septic arthritis, and skin and soft tissue infections. American Journal of Medicine 1985;79(5B):141‐5. - PubMed
Tascini 2009 {published data only}
    1. Tascini C, Tagliaferri E, Paolo A, Tacca M, Lambelet P, Menichetti F. Three‐times weekly teicoplanin as outpatient treatment of chronic osteoarticular infections. Journal of Chemotherapy 2009;21(4):421‐5. - PubMed

References to studies awaiting assessment

Barberán 2000 {published data only}
    1. Barberán J, Gomis M, Sánchez B, Hernández‐Salván J, García Del Salto L, Carroquino G, et al. Cefepime in the treatment of osteomyelitis caused by Gram negative bacilli [Cefepima en el tratamiento de la osteomielitis por bacilos gramnegativos]. Revista Espanola de Quimioterapia 2000;13(4):366‐73. - PubMed

References to ongoing studies

CTRI/2008/091/000060 {published data only}
    1. Saraf N, Mudgai M. A clinical trial to study the safety and efficacy of combination drugs, vancomycin and ceftriaxone compared to vancomycin in mild to severe bacterial infections. http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=100&EncHid=&... (accessed 12 August 2013) 2008.
EUCTR2009‐015744‐42‐GB {published data only}
    1. Oxford Radcliffe Hospital Trust (sponsor). Randomised open label study of oral versus intravenous antibiotic treatment for bone and joint infections requiring prolonged antibiotic treatment. http://apps.who.int/trialsearch/Trial.aspx?TrialID=EUCTR2009‐015744‐42‐GB (accessed 20 April 2013) 2009. [EUCTR2009‐015744‐42‐GB]
NCT00324922 {published data only}
    1. Ramers C, Taistman L, Harrington R, Chan J, Henley BM, Hawn TR, et al. A prospective randomised trial comparing vancomycin with trimethoprim/sulphamethoxazole for the treatment of MRSA osteomyelitis. http://clinicaltrials.gov/show/NCT00324922 (accessed 20 April 2013) 2006.

Additional references

Bourguignat 1996
    1. Bourguignat A, Ferard G, Jenny JY, Gaudias J, Kempf I. Diagnostic value of C‐reactive protein and transthyretin in bone infections of lower limb. Clinica Chimica Acta 1996;255(1):27‐38. - PubMed
Carek 2001
    1. Carek PJ, Dickerson LM, Sack JL. Diagnosis and management of osteomyelitis. American Family Physician 2001;63(12):2413‐20. - PubMed
Ciampolini 2000
    1. Ciampolini J, Harding KG. Pathophysiology of chronic bacterial osteomyelitis. Why do antibiotics fail so often?. Postgraduate Medical Journal 2000;76(898):479‐83. - PMC - PubMed
Cierny 1985
    1. Cierny G 3rd, Mader JT, Penninck JJ. A clinical staging system for adult osteomyelitis. Contemporary Orthopaedics 1985;10:17‐37. - PubMed
Cierny 2003
    1. Cierny G 3rd, Mader JT, Penninck JJ. A clinical staging system for adult osteomyelitis. Clinical Orthopaedic and Related Research 2003;414:7‐24. - PubMed
Cunha 2002
    1. Cunha BA. Osteomyelitis in elderly patients. Clinical Infectious Diseases 2002;35(3):287‐93. - PubMed
Darouiche 2004
    1. Darouiche RO. Treatment of infections associated with surgical implants. New England Journal of Medicine 2004;350(14):1422‐9. - PubMed
Eckardt 1994
    1. Eckardt JJ, Wirganowicz PZ, Mar T. An aggressive surgical approach to the management of chronic osteomyelitis. Clinical Orthopaedics and Related Research 1994;(298):229‐39. - PubMed
Ferard 2002
    1. Ferard G, Gaudias J, Bourguignat A, Ingenbleek Y. C‐reactive protein to transthyretin ratio for the early diagnosis and follow‐up of postoperative infection. Clinical Chemistry and Laboratory Medicine 2002;40(12):1334‐8. - PubMed
Gristina 1990
    1. Gristina AG, Naylor PT, Myrvik QN. Musculoskeletal infection, microbial adhesion, and antibiotic resistance. Infectious Disease Clinics of North America 1990;4(3):391‐408. - PubMed
Haas 1996
    1. Haas DW, McAndrew MP. Bacterial osteomyelitis in adults: evolving considerations in diagnosis and treatment. American Journal of Medicine 1996;101(5):550‐61. - PubMed
Haidar 2010
    1. Haidar R, Boghossian A, Atiyeh B. Duration of post‐surgical antibiotics in chronic osteomyelitis: empiric or evidence‐based?. International Journal of Infectious Diseases 2010;14(9):e752‐8. - PubMed
Higgins 2003
    1. Higgins JP, Tompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60. - PMC - PubMed
Higgins 2006
    1. Higgins JPT, Green S (editors). Highly sensitive search strategies for identifying reports of randomised controlled trials in MEDLINE. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]; Appendix 5b. www.cochrane.org/resources/handbook/hbook.htm (accessed 01 May 2007).
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Holtom 1999
    1. Holtom PD, Smith AM. Introduction to adult posttraumatic osteomyelitis of the tibia. Clinical Orthopaedics and Related Research 1999;(360):6‐13. - PubMed
Huber 2002
    1. Huber AM, Lam PY, Duffy CM, Yeung RS, Ditchfield M, Laxer D, et al. Chronic recurrent multifocal osteomyelitis: clinical outcomes after more than five years of follow‐up. Journal of Pediatrics 2002;141(2):198‐203. - PubMed
Johnston 2007
    1. Johnston BL, Conly JM. Osteomyelitis management: More art than science?. Canadian Journal of Infectious Diseases & Medical Microbiology 2007;18(2):115‐8. - PMC - PubMed
Karamanis 2008
    1. Karamanis EM, Matthaiou DK, Moraitis LI, Falagas ME. Fluoroquinolones versus ß‐lactam based regimens for the treatment of osteomyelitis: a meta‐analysis of randomized controlled trials. Spine 2008;33(10):e297‐e304. - PubMed
Lazarini 2005
    1. Lazzarini L, Lipsky BA, Mader JT. Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical trials?. International Journal of Infectious Diseases 2005;9(3):127‐38. - PubMed
Lazzarini 2002
    1. Lazzarini L, Lalla F, Mader JT. Long bone osteomyelitis. Current Infectious Disease Reports 2002;4(5):439‐45. - PubMed
Lew 2004
    1. Lew DP, Waldvogel FA. Osteomyelitis. Lancet 2004;364(9431):369‐79. - PubMed
Lipsky 1997
    1. Lipsky BA, Baker PD, Landon GC, Fernau R. Antibiotic therapy for diabetic foot infections: comparison of two parenteral‐to‐oral regimens. Clinical Infectious Diseases 1997;24(4):643‐8. - PubMed
Liu 2011
    1. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin‐resistant Staphylococcus aureus infections in adults and children: executive summary. Clinical Infectious Diseases 2011;52(3):285‐92. - PubMed
Mader 1992
    1. Mader JT, Norden C, Nelson JD, Calandra GB. Evaluation of new anti‐infective drugs for the treatment of osteomyelitis in adults. Infectious Diseases Society of America and the Food and Drug Administration. Clinical Infectious Diseases 1992;15(Suppl 1):S155‐61. - PubMed
Mader 1993
    1. Mader JT, Landon GC, Calhoun J. Antimicrobial treatment of osteomyelitis. Clinical Orthopaedics and Related Research 1993;(295):87‐95. - PubMed
Mader 1997a
    1. Mader JT, Shirtliff M, Calhoun JH. Staging and staging application in osteomyelitis. Clinical Infectious Diseases 1997;25(6):1303‐9. - PubMed
Mader 1999a
    1. Mader JT, Shirtliff ME, Bergquist SC, Calhoun J. Antimicrobial treatment of chronic osteomyelitis. Clinical Orthopaedics and Related Research 1999;(360):47‐65. - PubMed
Mader 1999b
    1. Mader JT, Cripps MW, Calhoun JH. Adult posttraumatic osteomyelitis of the tibia. Clinical Orthopaedics and Related Research 1999;(360):14‐21. - PubMed
Mader 2001
    1. Mader JT, Wang J, Calhoun JH. Antibiotic therapy for musculoskeletal infections. Journal of Bone and Joint Surgery ‐ American Volume 2001;83(12):1878‐90.
Murphy 2011
    1. Murphy RA, Ronat JB, Fakhri RM, Herard P, Blackwell N, Abgrall S, et al. Multidrug‐resistant chronic osteomyelitis complicating war injury in Iraqi civilians. Journal of Trauma‐Injury Infection and Critical Care 2011;71(1):252‐4. - PubMed
Parsons 2004
    1. Parson B, Strauss E. Surgical management of chronic osteomyelitis. American Journal of Surgery 2004;188(1A Suppl):57‐66. - PubMed
Pollard 2006
    1. Pollard TC, Newman JE, Barlow NJ, Price JD, Willett KM. Deep wound infection after proximal femoral fracture: consequences and costs. Journal of Hospital Infection 2006;63(2):133‐9. - PubMed
Review Manager (RevMan) [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
Rissing 1997
    1. Rissing JP. Antimicrobial therapy for chronic osteomyelitis in adults: role of the quinolones. Clinical Infectious Diseases 1997;25(6):1327‐33. - PubMed
Saginur 2006
    1. Saginur R, Denis M, Ferris W, Aron SD, Chang F, Lee C, et al. Multiple combination bactericidal testing of Staphylococcal biofilms from implant‐associated infections. Antimicrobial Agents and Chemotherapy 2006;50(1):55‐61. - PMC - PubMed
Senneville 2006
    1. Senneville E, Melliez H, Beltrand E, Legout L, Valette M, Cazaubiel M. Culture of percutaneous bone biopsy specimens for diagnosis of diabetic foot osteomyelitis: concordance with ulcer swab cultures. Clinical of Infectious Diseases 2006;42(1):57‐62. - PubMed
Sheehy 2010
    1. Sheehy SH, Atkins BA, Bejon P, Byren I, Wyllie D, Athanasou NA, et al. The microbiology of chronic osteomyelitis: prevalence of resistance to common empirical anti‐microbial regimens. Journal of Infection 2010;60(5):338‐43. - PubMed
Simpson 2001
    1. Simpson AH, Deakin M, Latham JM. Chronic osteomyelitis. The effect of the extent of surgical resection on infection‐free survival. Journal of Bone and Joint Surgery ‐ British Volume 2001;83(3):403‐7. - PubMed
Spellberg 2012
    1. Spellberg B, Lipsky BA. Systemic antibiotic therapy for chronic osteomyelitis in adults. Clinical Infectious Diseases 2012;54(3):393‐407. - PMC - PubMed
Stengel 2001
    1. Stengel D, Bauwens K, Sehouli J, Ekkernkamp A, Porzsolt F. Systematic review and meta‐analysis of antibiotic therapy for bone and joint infections. Lancet Infectious Diseases 2001;1(3):175‐88. - PubMed
Swiontkowski 1999
    1. Swiontkowski MF, Hanel DP, Vedder NB, Schwappach JR. A comparison of short‐ and long‐term intravenous antibiotic therapy in the postoperative management of adult osteomyelitis. Journal of Bone and Joint Surgery ‐ British Volume 1999;81(6):1046‐50. - PubMed
Trampuz 2006
    1. Trampuz A, Zimmerli W. Diagnosis and treatment of infections associated with fracture‐fixation devices. Injury 2006;37(Suppl 2):S59‐66. - PubMed
Waldvogel 1970
    1. Waldvogel FA, Medoff G, Swartz MN. Treatment of osteomyelitis. New England Journal of Medicine 1970;283(15):822. - PubMed
Waldvogel 1980
    1. Waldvogel FA, Papageorgiou PS. Osteomyelitis: the past decade. New England Journal of Medicine 1980;303(7):360‐70. - PubMed
Walenkamp 1997
    1. Walenkamp GHIM. Chronic osteomyelitis. Acta Orthopaedica Scandinavica 1997;68(5):497‐506. - PubMed
Walter 2012
    1. Walter G, Kemmerer M, Kappler C, Hoffmann R. Treatment algorithms for chronic osteomyelitis. Deutsches Ärzteblatt International 2012;109(14):257‐64. - PMC - PubMed
Zuluaga 2002
    1. Zuluaga AF, Galvis W, Jaimes F, Vesga O. Lack of microbiological concordance between bone and non‐bone specimens in chronic osteomyelitis: an observational study. BMC Infectious Diseases 2002;2(8):1‐7. - PMC - PubMed

References to other published versions of this review

Conterno 2009
    1. Conterno LO, Silva Filho CR. Antibiotics for treating chronic osteomyelitis in adults. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD004439.pub2] - DOI - PubMed

Publication types

Substances

LinkOut - more resources